Welcome to BioSeeker Group!

Triple Analysis: Breast Cancer, Prostate Cancer and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4261
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Breast Cancer, Prostate Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Prostate Cancer and Peptides.

    To find out more about Triple Analysis: Breast Cancer, Prostate Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Prostate Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
10 Disclaimer 1724
Figures: Includes 8 Figures
Tables: Includes 309 Tables
Total Number of Pages: 1,755

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
Abiogen
Acceleron Pharma
Access
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affymax
Agenus
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
Anchor Therapeutics
AndroBioSys
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
ArQule
Array BioPharma
Ascend Therapeutics
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVI BioPharma
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Beta Pharma
Betagenon
Bioenvision
Biogen Idec
Biokine Therapeutics
BioLineRx
BioMarin
BioNetWorks
Bionovo
BioSante
Biostar
Biotecnol
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
Chemokine Therapeutics
Chiasma
Chiesi
Chong Kun Dang
Circadian Technologies
Cleveland BioLabs
Clinuvel
Colby
CompleGen
Compugen
Cosmo Bioscience
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Dendreon
Digna Biotech
Domainex
Dong-A
Dongkook Pharm
Douglas
ECI
Eisai
Elara Pharmaceuticals
ElexoPharm
Eli Lilly
Endo Pharmaceuticals
Endoceutics
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
Eucodis
EUSA Pharma
Exelixis
Expression Drug Designs
Ferring
Formula Pharmaceuticals
Fresenius
Galectin Therapeutics
Galena Biopharma
Gemin X Pharmaceuticals
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GlyTag
Got-a-Gene
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
GTx
Harbor BioSciences
Heidelberg Pharma
Hoffmann-La Roche
Hospira
Human Genome Sciences
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intarcia Therapeutics
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jina Pharmaceuticals
Johnson & Johnson
KAEL-GemVax
Karo Bio
Karyon-CTT
Kiadis
Kinex
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Marina Biotech
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
MetaMol Theranostics
MethylGene
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
NexGenix Pharmaceuticals
Nidus Laboratories
NIH
Nimbus Discovery
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
Oncolix
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Pacific Biotech
Paladin Labs
PanaGin
Pantarhei Bioscience
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protagonist
PTC Therapeutics
Q Chip
QLT
R&R
Radient Pharmaceuticals
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
Sareum
Savient Pharmaceuticals
SBIO
Schering-Plough
SciClone Pharmaceuticals
SEEK
SeleXel
Selvita
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shenogen
Shire
Siena Biotech
Sigma-Tau
Sirnaomics
Soligenix
Sophiris Bio
Spectrum Pharmaceuticals
SRI International
Sun Pharma Advanced Research
Supratek Pharma
Switch Pharma
Synageva BioPharma
Synta Pharmaceuticals
Tactic Pharma
Taiho
Taiwan Liposome Company
Takeda
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Tau Therapeutics
Taxolog
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaxon Biotech
Velacor Therapeutics
Verastem
Vernalis
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroMed
ViroTarg
VM Discovery
Wyeth
Xerion
Xigen
Xoma
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
177-Lu-AMBA
17ß-hydroxysteroid dehydrogenase-1 inhibitors
2-methoxyestradiol
2aG4-IL-2 fus protein + PS MAb
4-hydroxytamoxifen
5-FU
852A
9-aminocamptothecin
A6
AB-16B5
abarelix
abiraterone acetate
ABT-510
ACC inhibitor
acolbifene
adecatumumab
aderbasib
Adva-27a
AE-37
AEE-788
AEG-35156
AEZS-108
afamelanotide
afatinib
aflibercept
AFM-21
AG-1
agatolimod
aglycon protopanaxadiol
ALT-801
alvespimycin hydrochloride
alvocidib
amatuximab
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
amuvatinib
anastrozole
androgen receptor antagonist
angiopep+paclitaxel
Angiozyme
annamycin
anti-C35 MAb
anti-HER-2/neu antisense
anti-HER2 MAb
anti-HER2neu scFv
anti-Hsp90-alpha MAbs
anti-PCDGF MAbs
anticancers
antiestrogen
APC-100
APR-246
apricoxib
AR-002
AR-004
AR-7BD-33-11A
ARC-100
ARQ-197
ARQ-621
ARRY-380
arzoxifene hydrochloride
AS-1402
ASP-08126
atamestane
ATN-224
atrasentan
Auto TAG vaccine
AUY-922
AVE-1642
AVI-4126
avorelin
AVX-701
axitinib
AZD-1480
AZD-4547
AZD-4877
AZD-4992
AZD-8931
bafetinib
BAL-27862
banoxantrone
becatecarin
belinostat
bevacizumab
BEZ-235
BGT-226
BIBF-1120
bicalutamide
BIW-8556
BMN-673
BMS-599626
BMS-690514
BMS-753493
BMS-754807
BMS-777607
BMS-936558
BN-107
bortezomib
bosutinib
BP-GMAX-CD1
brca2
breast cancer therapy
breast cancer vaccine
BreMel/TNF-alpha
BrevaRex MAb
brivanib alaninate
brivudine
buserelin
BZL-101
CAB-051
Cabozantinib
cancer therapy (1)
cancer therapy (2)
canertinib dihydrochloride
canfosfamide hydrochloride
capecitabine
carbetocin
carlumab
catumaxomab
CBP-501
CDX-1307
CEA cancer vaccine
cediranib
celecoxib
cetuximab
CGX-0682
CH-4986399
CHF-4227
cilengitide
cixutumumab
clofarabine
CNF-2024
contusugene ladenovec
corticorelin acetate
CP-724714
crolibulin
CTCE-9908
CTP-37
CUDC-101
custirsen
CVac
CX-4945
CYN-101
D-3263
dabigatran etexilate
dalotuzumab
danusertib
dasatinib
daunorubicin
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
Diflomotecan
dinaciclib
docetaxel
docetaxel (1)
docetaxel (2)
docetaxel (3)
docetaxel (4)
docetaxel (5)
docetaxel MAb
dovitinib lactate
doxercalciferol
doxifluridine
doxorubicin
doxorubicin (1)
doxorubicin (10)
doxorubicin (11)
doxorubicin (2)
doxorubicin (3)
doxorubicin (4)
doxorubicin (5)
doxorubicin (6)
doxorubicin (7)
doxorubicin (8)
doxorubicin (9)
doxorubicin citrate
dutasteride
DXL-702
E-75
E39
ECI-301
elomotecan
elsamitrucin
emepepimut-S
endostatin
endoxifen
eniluracil
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
epothilone D
erlotinib
ERR antagonists
ertumaxomab
estetrol
estramustine phosphate sodium
estrogen inhibitors
ethinyl estradiol sulfonate
everolimus
exatecan mesylate
exemestane
Exherin
exisulind
EZH2
F16-IL2
fadrozole
FASN inhibitors
figitumumab
flt-4 kinase inhibitors
flutamide
formestane (1)
formestane (2)
fosfluridine tidoxil
FPI-01
fulvestrant
fusion toxins
Galactomycin-UCLT
galarubicin hydrochloride
ganitumab
gataparsen
GDC-0980
gefitinib
gimatecan
glembatumumab vedotin
GlyB4
golnerminogene pradenovec
goserelin
goserelin acetate ER
GPR40 antagonists
GSK-1059615
GSK-2130579A
GSK-2302024A
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HAS2 inhibitor
HE-3235
Her-2/Neu peptides
HER2 vaccine
her2/neu antigen
Her2/neu gene therapy
histrelin
huBrE-3 tiuxetan
HuMax-Her2
HuMax-VEGF
icotinib hydrochloride
icrucumab
idronoxil
IGF-1 receptor inhibitor
IGN-101
IKKe/TBK1 inhibitor
imatinib mesilate
imetelstat
IMGN-388
imMucin
immunogene therapy
IMO-2055
IMP-321
Imuteran
INCB-028060
indisulam
inecalcitol
ING-1
ingenol mebutate
INGN-225
INGN-241
inherbins
iniparib
INNO-206
INSM-18
interferon (ß1a)
interleukins
intetumumab
IPH-3102
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
irosustat
ISA-P53-01
ispinesib mesylate
JMR-132
kahalalide F
KW-2170
KX2-391
labetuzumab
labetuzumab-SN-38
lanreotide
lapatinib ditosylate
lapuleucel-T
larotaxel
lasofoxifene
lenvatinib
leptin antagonists
lestaurtinib
letrozole
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
linsitinib
LIP-131I
LipoVIL12
litronesib
lonafarnib
lonaprisan
LOR-2040
LOR-2501
Lovaxin B
LY-2157299
LY-2275796
MAGH-22
MCS-110
MDV-3100
MDX-1140
MDX-1379
ME-103
MEDI-547
Mesd-based peptides
MetXia
MGN-1601
MGN-1703
milataxel
mitoxantrone
MK-2206
MKC-1
MLN-8237
MM-111
MM-121
MORAb-004
motesanib diphosphate
motexafin gadolinium
MP-529
MS-209
MT-110
MUC-1 vaccine
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
NAFB001
neratinib
netupitant
nilutamide
nimotuzumab
NK-012
NL-0031
nolatrexed dihydrochloride
NXD-30001
OB-cadherin antibodies
oblimersen sodium
OCM-111
OCM-8054
OCM-8224
octreotide
octreotide, LAR
OGX-225
OGX-427
olaparib
olaratumab
ON-01910
ON-045270
onartuzumab
Onco-L TCS
oncolytic viruses
orteronel
OSI-7904L
osteolytic disease therapy
Osteopontin-c inhibitor


OTS-102
ozarelix
P276-00
paclitaxel
paclitaxel (1)
paclitaxel (10)
paclitaxel (11)
paclitaxel (12)
paclitaxel (13)
paclitaxel (14)
paclitaxel (2)
paclitaxel (3)
paclitaxel (4)
paclitaxel (5)
paclitaxel (6)
paclitaxel (7)
paclitaxel (8)
paclitaxel (9)
paclitaxel polyglumex
paclitaxel-DHA
panitumumab
PankoPep
panobinostat
PANVAC-VF
pasireotide
pasireotide LAR
patupilone
pazopanib hydrochloride
PD-0325901
PD-0332991
pelitinib
pemetrexed disodium
pentamidine isethionate
peptidomimetics
perifosine
pertuzumab
PhG-alpha-1
pixantrone
PKI-179
PKI-587
plitidepsin
PLX-3397
polyclonal antibody stimulator
pralatrexate
Prolanta
Prolanta ER
ProstAtak
prostate cancer therapy
PROSTVAC
PRX-302
PRX-321
PSK-3668
PTC-299
PX-104.1
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
R-763
radiotherapeutic
raloxifene hydrochloride
ramucirumab
retaspimycin
Reximmune-C
Rexin-G
RG-1507
RG-7321
rhErbB3-f
ridaforolimus
rilotumumab
rindopepimut
rinfabate
romidepsin
romurtide
RR-310
rubitecan
ruxolitinib
S1P3 inhibitor
sabarubicin
sagopilone
SAR-566658
saracatinib
sargramostim
SB-939
SBC-202
Sch-57050
SEL-24-1
seliciclib
selumetinib
semaxanib
seocalcitol
SERM + toxin
SF-1126
siltuximab
simotaxel
sipuleucel-T
siRNA gp96 therapy
SM3
SN-38 (1)
SN-38 (2)
SNG-163
SNG-8023
SNG-8038
sorafenib tosylate
sotatercept
SPC-2968
SR-13668
SR-16157
SR-31747
ß-lapachone
STA-9090
steroid sulfatase inhibitor
STP-503
SU-14813
SU-6668
sunitinib malate
Survivac
survivin-2B
Symadex
TAK-448
talminogene laherparepvec
tamoxifen (1)
tamoxifen (2)
tamoxifen, oral liquid
tandutinib
tanespimycin
tariquidar
TAS-108
tasquinimod
tegafur + uracil
telomerase vaccine
temsirolimus
Tenarad
TG-4010
thiocoraline
thymalfasin
thymectacin
tipifarnib
tivozanib
TLK-58130
TLN-4601
TM-30339
TNF + paclitaxel
TNF-alpha
TOK-001
toremifene citrate
trastuzumab (1)
trastuzumab (2)
trastuzumab (3)
trastuzumab emtansine
trastuzumab-MMAE conjugate
TRC-105
tremelimumab
triapine
triciribine phosphate
trilostane
triptorelin
triptorelin pamoate
TroVax
TS-1
TTL-2019
TTL-3101
tucotuzumab celmoleukin
UCN-01
V-930
V935
vandetanib
vapreotide, immediate-release
varlitinib
vatalanib
veliparib
vismodegib
vitespen
VM-206
VS-4718
VS-507
VS-5095
VX-001
WX-671
WX-UK1
XL-147
XL-647
XL-765
Y-90-labetuzumab
YM-155
Zemab
zibotentan
ZYC-300

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Prostate Cancer and Peptides.
    To find out more about Triple Analysis: Breast Cancer, Prostate Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Prostate Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Triple Analysis: Leukemia, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Notch Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More


Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More